The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trifluridine/tipiracil (TAS-102) in combination with anti-EGFR re-challenge versus TAS-102 plus anti-VEGF in patients with mCRC who experienced first-line anti-EGFR-based chemotherapy.
 
Ching Tso Chen
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Merck; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer
 
Yi-Hsin Liang
No Relationships to Disclose
 
Kun-Huei Yeh
Honoraria - Amgen; Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Merck; MSD; MSD Oncology; Novartis; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Roche; Takeda; TTY Biopharm
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Lilly; MSD; MSD Oncology; Novartis; Ono Pharmaceutical; Ono Pharmaceutical; Roche; Takeda
Speakers' Bureau - Merck